S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
Leichman C, McDonough S, Smalley S, Billingsley K, Lenz H, Beldner M, Hezel A, Velasco M, Guthrie K, Blanke C, Hochster H. S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC). Journal Of Clinical Oncology 2015, 33: 3516-3516. DOI: 10.1200/jco.2015.33.15_suppl.3516.Peer-Reviewed Original Research